{"nctId":"NCT02322333","briefTitle":"MLD10 in the Prevention of Migraine in Adults","startDateStruct":{"date":"2015-03","type":"ACTUAL"},"conditions":["Migraine"],"count":157,"armGroups":[{"label":"MLD10","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MLD10"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MLD10","otherNames":["elemental magnesium"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. male or female, in otherwise good health, 18 to 65 years of age.\n2. history of frequent episodic migraine (3-14 migraine days per month) (with or without aura) according to the International Classification of Headache Disorders-3beta for at least 3 months.\n3. onset of migraine before age 50.\n4. stable history of migraine at least 3 months prior to screening.\n5. not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.\n6. if female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as listed:\n\n   * complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for 7 days after completion or premature discontinuation from the study; surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); sterilization of male partner when in a monogamous relationship; intrauterine device with published data showing lowest expected failure rate is less than 1% per year; double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.\n7. completion of online diary must be â‰¥ 80% compliance, unless otherwise approved by the Sponsor and/or Clinvest.\n\nExclusion Criteria:\n\n1. unable to understand the study requirements, the informed consent, or complete headache records as required per protocol.\n2. pregnant, actively trying to become pregnant, or breast-feeding.\n3. diagnosed with International Classification of Headache Disorders-3beta criteria for Chronic Migraine within 3 months prior to screening, at the time of screening, and/or during the baseline period.\n4. experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine within the last year.\n5. history of medication overuse headache (MOH) (Appendix II) in the 3 months prior to study enrollment or during the baseline phase.\n6. history of medication overuse (MO) of ergotamines, triptans, opioids, analgesics, NSAIDS and combination therapies, as defined by ICHD-3beta criteria and/or MO during baseline period.\n7. history of substance abuse and/or dependence, in the opinion of the Investigator.\n8. history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study.\n9. unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure.\n10. suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events.\n11. has significant risk of suicide, defined as a \"yes\" answer to any of the following questions on the Columbia-Suicide Severity Rating Scale (C-SSRS), either at the screening visit (when assessing the prior 12 months) or at visit 2 (when assessing time since the screening visit):\n\n    1. Questions 4 or 5 on the suicidal ideation section\n    2. Any question on any item in the suicidal behavior section\n12. any psychiatric disorder with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in their ability to complete study activities.\n13. hypersensitivity, intolerance, or contraindication to the use of magnesium L-lactate dehydrate or any of its components.\n14. received any investigational agents within 30 days prior to Visit 1.\n15. plans to participate in another clinical study at any time during this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Migraine Headache Days","description":"Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment period month 3 in subjects treated with MLD10 versus placebo.\n\nA migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3beta criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics \\[simple analgesics combined with opioids or barbiturate with or without caffeine\\]).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":"2.94"},{"groupId":"OG001","value":"6.92","spread":"2.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.53","spread":"4.43"},{"groupId":"OG001","value":"4.79","spread":"4.20"}]}]}]},{"type":"SECONDARY","title":"Headache Days","description":"Comparison of the change from baseline of subjects treated with MLD10 versus placebo in the frequency of headache days during the 3 month treatment period.\n\nA headache day will be defined as any day not classified as a migraine day, but recorded headache of any severity and/or duration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":"3.16"},{"groupId":"OG001","value":"9.20","spread":"3.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.89","spread":"5.36"},{"groupId":"OG001","value":"6.25","spread":"4.81"}]}]}]},{"type":"SECONDARY","title":"Headache Duration","description":"Change from baseline (28 day period) in the total cumulative minutes of headache during each 28-day treatment period month 1, 2, \\& 3 in subjects treated with MLD10 versus placebo.\n\nAll headaches and/or migraines will be including in this outcome analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"410.03","spread":"182.26"},{"groupId":"OG001","value":"396.48","spread":"166.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430.88","spread":"242.35"},{"groupId":"OG001","value":"369.03","spread":"188.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"443.89","spread":"233.60"},{"groupId":"OG001","value":"364.21","spread":"186.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"429.26","spread":"228.59"},{"groupId":"OG001","value":"383.70","spread":"204.06"}]}]}]},{"type":"SECONDARY","title":"Pain Severity","description":"Change from baseline (28 day period) in the average pain severity at time of onset compared to each 28-day treatment period month 1, 2, \\& 3 in subjects treated with MLD10 versus placebo. Headache pain severity was measured on a scale 1 = Mild, 2 = Moderate, 3 = Severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"0.50"},{"groupId":"OG001","value":"2.06","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":"0.54"},{"groupId":"OG001","value":"1.93","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.54"},{"groupId":"OG001","value":"1.85","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.01","spread":"0.49"},{"groupId":"OG001","value":"1.86","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Acute Medication Usage","description":"Change from baseline (28 day period) in the total number of acute headache pain medications used during each 28 day treatment period month 1, 2, \\& 3 in subjects treated with MLD10 versus placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.67","spread":"7.64"},{"groupId":"OG001","value":"11.08","spread":"6.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.74","spread":"8.15"},{"groupId":"OG001","value":"8.13","spread":"6.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.12","spread":"7.08"},{"groupId":"OG001","value":"8.61","spread":"8.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.18","spread":"8.40"},{"groupId":"OG001","value":"8.25","spread":"8.67"}]}]}]},{"type":"SECONDARY","title":"Migraine Disability Assessment Scale (MIDAS)","description":"Change from Visit 2 to Visit 5 in the total MIDAS score in subjects treated with MLD10 versus placebo.\n\nThe MIDAS test determines how severely migraines affect daily functioning. The responses of a variety of questions will be scored according to the questionnaire's scoring guide. A total score will be calculated ranging from 0-93. A score of 0-5 indicates little or no disability, 6-10 mild disability, 11-20, moderate disability, 21+ severe disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.94","spread":"34.56"},{"groupId":"OG001","value":"27.03","spread":"25.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.14","spread":"33.91"},{"groupId":"OG001","value":"21.40","spread":"18.64"}]}]}]},{"type":"SECONDARY","title":"Subject Global Impression of Change (SGIC)","description":"Comparison of SGIC at Visit 5 in subjects treated with MLD10 versus placebo.\n\nGlobal impression of change rated by the subject will be assessed using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.987"},{"groupId":"OG001","value":"1.10","spread":"1.23"}]}]}]},{"type":"SECONDARY","title":"Physician Global Impression of Change (PGIC)","description":"Comparison of PGIC at Visit 5 in subjects treated with MLD10 versus placebo.\n\nThe PGIC will be an impression of change rated by the investigator using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"1.09"},{"groupId":"OG001","value":"1.06","spread":"1.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":80},"commonTop":["Diarrhoea","Nausea","Viral upper respiratory tract infection","Dizziness","Sinusitis"]}}}